Patents by Inventor Bard Indrevoll
Bard Indrevoll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230072421Abstract: A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 24, 2020Publication date: March 9, 2023Applicants: Bayer AS, Bayer AktiengesellschaftInventors: Niels BÖHNKE, Sabine ZITZMANN-KOLBE, Stefanie HAMMER, Sven WITTROCK, Donald BIERER, Thorsten POETHKO, Hans BRIEM, Holger Magnus STEUBER, Martina SCHÄFER, Robin Michael MEIER, Arif CELIK, Cornelia PREUSSE, Antje ROTTMANN, Nicolas WERBECK, Alexander KRISTIAN, Bård INDREVOLL, Alan CUTHBERTSON, Alex PAPPLE
-
Patent number: 10548995Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with the radioisotope 18F. The invention provides a method of preparation of lyophilised compositions of aminooxy-functionalised biomolecules, as well as radiolabelling methods using the purified materials. Also provided are lyophilised compositions and cassettes comprising such purified compositions. The invention is particularly suitable for use with an automated synthesizer apparatus.Type: GrantFiled: August 20, 2014Date of Patent: February 4, 2020Assignee: GE HEALTHCARE LIMITEDInventors: Willy Skjold, Bard Indrevoll
-
Patent number: 10201625Abstract: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).Type: GrantFiled: March 1, 2012Date of Patent: February 12, 2019Assignees: IMPERIAL COLLEGE, GE HEALTHCARE LIMITEDInventors: Sajinker Kaur Luthra, Julius Leyton, Eric Ofori Aboagye, Lisa Iddon, Bard Indrevoll, Matthias Eberhard Glaser, Alan Cuthbertson
-
Publication number: 20170044080Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.Type: ApplicationFiled: November 1, 2016Publication date: February 16, 2017Inventor: Bard Indrevoll
-
Patent number: 9493504Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.Type: GrantFiled: December 1, 2011Date of Patent: November 15, 2016Assignee: GE Healthcare LimitedInventor: Bard Indrevoll
-
Publication number: 20160166717Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with the radioisotope 18F. The invention provides a method of preparation of lyophilised compositions of aminooxy-functionalised biomolecules, as well as radiolabelling methods using the purified materials. Also provided are lyophilised compositions and cassettes comprising such purified compositions. The invention is particularly suitable for use with an automated synthesizer apparatus.Type: ApplicationFiled: August 20, 2014Publication date: June 16, 2016Applicant: GE HEALTHCARE LIMITEDInventors: Willy Skjold, Bard Indrevoll
-
Patent number: 9259496Abstract: The present invention relates to technetium imaging agents comprising radiolabeled c-Met binding peptides suitable for SPECT or PET imaging in vivo. The c-Met binding peptides are labelled via chelator conjugates. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the diagnosis of cancer.Type: GrantFiled: March 2, 2012Date of Patent: February 16, 2016Assignee: GE Healthcare LimitedInventors: Peter Brian Iveson, Bard Indrevoll, Ben Newton, Rajiv Bhalla, Edvin Wilhelm Johannesen
-
Patent number: 9061080Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: December 19, 2011Date of Patent: June 23, 2015Assignee: GE HEALTHCARE LIMITEDInventors: Duncan Hiscock, Bard Indrevoll, Peter Iveson, Matthias Eberhard Glaser, Rajiv Bhalla, Anthony Wilson
-
Publication number: 20140004041Abstract: The present invention relates to technetium imaging agents comprising radiolabeled c-Met binding peptides suitable for SPECT or PET imaging in vivo. The c-Met binding peptides are labelled via chelator conjugates. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the diagnosis of cancer.Type: ApplicationFiled: March 2, 2012Publication date: January 2, 2014Applicant: GE HEALTHCARE LIMITEDInventors: Peter Brian Iveson, Bard Indrevoll, Ben Newton, Rajiv Bhalla, Edvin Wilhelm Johannesen
-
Publication number: 20130343990Abstract: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).Type: ApplicationFiled: March 1, 2012Publication date: December 26, 2013Applicants: IMPERIAL COLLEGE, GE HEALTHCARE LIMITEDInventors: Sajinker Kaur Luthra, Julius Leyton, Eric Ofori Aboagye, Lisa Iddon, Bard Indrevoll, Matthias Eberhard Glaser, Alan Cuthbertson
-
Publication number: 20130295010Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: December 19, 2011Publication date: November 7, 2013Inventors: Duncan Hiscock, Bard Indrevoll, Peter Iveson, Matthias Eberhard Glaser, Rajiv Bhalla, Anthony Wilson
-
Publication number: 20130259803Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.Type: ApplicationFiled: December 1, 2011Publication date: October 3, 2013Applicant: GE HEALTHCARE LIMITEDInventor: Bard Indrevoll
-
Publication number: 20130251632Abstract: The present invention relates to radiopharmaceutical imaging in vivo of apoptosis and other forms of cell death. The invention provides PET imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.Type: ApplicationFiled: December 1, 2011Publication date: September 26, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Duncan Hiscock, Bente Elizabeth Arbo, Graeme Walter Mcrobbie, Bard Indrevoll, Rajiv Bhalla
-
Publication number: 20130189186Abstract: The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.Type: ApplicationFiled: September 27, 2011Publication date: July 25, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Bard Indrevoll, Duncan Hiscock, Bente Elizabeth Arbo, Rajiv Bhalla, Matthias Eberhard Glaser, Graeme Walter McRobbie
-
Patent number: 8404802Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.Type: GrantFiled: March 24, 2008Date of Patent: March 26, 2013Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bard Indrevoll
-
Patent number: 8299030Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: August 8, 2011Date of Patent: October 30, 2012Assignee: GE Healthcare LimitedInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Publication number: 20120020882Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: ApplicationFiled: August 8, 2011Publication date: January 26, 2012Applicant: GE HEALTHCARE ASInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Patent number: 7994134Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: April 15, 2009Date of Patent: August 9, 2011Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bård Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Patent number: 7785566Abstract: The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.Type: GrantFiled: November 5, 2004Date of Patent: August 31, 2010Assignee: GE Healthcare, Inc.Inventors: Alan Cuthbertson, Bard Indrevoll, Morten Eriksen
-
Patent number: 7608243Abstract: The invention relates to new peptide-based compounds and their use in diagnostic optical imaging. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labeled with fluorescein and may be used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases.Type: GrantFiled: July 7, 2004Date of Patent: October 27, 2009Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken